Skip to content

FAPET study

[68Ga]Ga-HKG301 PET imaging in patients with malignant solid tumors: the FAPET study - FAPET study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051260002
Enrollment
120
Registered
2026-04-07
Start date
2026-04-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecologic malignancy, gastric cancer, head and neck cancer, pancreas cancer and breast cancer malignant solid tumors

Interventions

Perform [68Ga]Ga- HKG301 PET and [18F]FDG PET in patients with malignant solid tumors at the time of staging, re-staging, and Neoadjuvant therapy.

Sponsors

Nakamoto Yuji
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients diagnosed with malignant solid tumors, including gynecologic malignancy, gastric cancer, head and neck cancer, pancreas cancer and breast cancer, on histopathological examination, those strongly suspected of having the malignant solid tumors clinically or radiologically, or those with a history of the malignant solid tumors and suspicious of their metastasis or recurrence. 2)Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 or 2. 3)Women or men who are at least 18 years of age at the time consent is obtained. 4)Written consent for participation in the study has been obtained from the patient themselves.

Exclusion criteria

Exclusion criteria: 1)Previous history of allergy to [68Ga]Ga-FAP-targeted PET tracers. 2)Pregnant or breast-feeding 3)Patients in extremely poor general condition or with significant communication difficulties who are expected to have difficulty completing the examination. 4)Others who are deemed inappropriate as research subjects by the principal investigator, the subinvestigator, or the co-investigators.

Design outcomes

Primary

MeasureTime frame
Diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value, and accuracy) of [68Ga]Ga-HKG301 PET in staging and restaging of malignant solid tumors.

Secondary

MeasureTime frame
1)Exploring the utility of [68Ga]Ga-HKG301 PET for patients treated with Neoadjuvant therapy 2)[68Ga]Ga-HKG301 Biomarker search for PET-positive malignant solid tumors 3)Association of [68Ga]Ga-HKG301 accumulation with ultrasound elastography findings in breast cancer

Contacts

Public ContactKanae Miyake

Kyoto University Graduate School of Medicine

kanaek@kuhp.kyoto-u.ac.jp+81-75-751-3760

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026